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ABSTRACT
Pharyngitis is primarily a viral infection of the respiratory tract, followed by secondary bacterial invasion due to weakening 
of  local  defenses.  Influenza  A  and  rhinoviruses  are  principally  involved,  the  influenza  virus  having  much  higher 
pathogenicity, however, than rhinoviruses which usually cause the common cough and cold without severe damage to the 
respiratory mucosa. Following initial infection, the virus enters the cells only for multiplication and almost all virulent virus 
particles subsequently produced are shed onto the throat surface. From the throat surface, the virions infect new healthy 
cells, damaging the throat mucosa, and creating a favorable ground for secondary bacterial colonization which is the cause 
of almost all symptoms of throat infection (sore throat, strep throat). The virus’ complex structure, its constant mutation, the 
variety of its surface glycoproteins, as well as the role of topical proteases helping virus entry and virus – bacteria symbiosis 
must all be taken into account in designing an effective treatment, acting on multiple parameters. As most viruses and all 
bacteria are present on the throat’s outer lining, treatment should be designed to act topically on the surface of the pharynx, 
which also minimizes side effects. Until 2012, no topical antiviral drugs were available and almost all treatment strategies 
were  directed  to  relieve  only  the  symptomatic  manifestations  of  throat  infections.  Anti-influenza  vaccination  is  still 
considered the best preventive measure, while the use of intracellular virus inhibitors is strictly limited to severe cases as 
they were not found to be very effective once throat infection is established. The recent development of non-specific topical 
virus glycoprotein inhibitors, incorporated in a filmogen glycerol solution for an increased duration of action, represents a
breakthrough yet relatively simple scientific approach for the treatment of viral throat infections accompanied by secondary 
bacterial infection. In this review, we analyze the whole process of viral throat infection, virus – bacteria interactions on the 
throat surface, currently available treatments and their drawbacks, and this innovative therapeutic approach consisting in 
virus glycoprotein inhibitors in an osmotic solution, destined to totally change the future treatment of throat infections.
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INTRODUCTION
The common cold and throat infections are the most frequent 
illnesses  in  the  world.  Characteristic  symptoms  include 
cough,  cold,  throat  pain,  sudden  onset of fever,  weakness, 
runny nose, and headache, occasionally followed by rhinitis 
and rhinosinusitis.  Most people recover within one to two 
weeks, when the  body’s defense  mechanisms are activated 
and  neutralize  the  causative  pathogen,  but  in  weakened 
populations  the  infection  may  spread  and  cause 
complications, especially with infections by influenza A and 
B viruses. 
[1]
Depending  on  the  epidemic’s  severity,  nearly  20%  of  the 
world population suffers each year from common cold-
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associated throat infection, costing 100s of billion Euros in 
healthcare and lost productivity, whereas the influenza virus 
affects about 5 to 15% of the population in Europe 
[2] and the 
US,  generating  economic  losses  between  US$  70  &  170 
billion each year (WHO estimation). 
[3] Every year, influenza 
epidemics are thought to result in 3 to 5 million severe cases 
in  Europe  alone,  and  between  250  000  and  500  000 
associated  deaths  worldwide,  most  deaths  in  industrialized 
countries occurring among the elderly over 65 years of age. 
[2]
Throat infections are chiefly of viral etiology, with secondary 
bacterial  infection  ensuing,  as  both  pathogens  often  act 
symbiotically. Although viral pathogenesis is a prerequisite 
for  subsequent  infections,  viruses  and  bacteria  may  be 
present in the naso-pharynx without causing any respiratory 
symptoms.  The  upper  respiratory  tract  hosts  a  complex 
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subject  to  synergistic  and  competitive  interspecies 
interactions, but disturbances in the equilibrium of bacterial 
or viral populations may lead to overgrowth and invasion. 
[4]  
In the majority of throat infections, only a few virus particles 
first come into contact with the pharyngeal mucosa, then start 
multiplying and liberating a huge amount of active free virus 
particles on the throat surface. When newly liberated virions 
attack healthy cells, the dead and dying cells and resulting 
minute mucosal damage create an environment favorable to 
opportunistic bacterial growth.  Recent findings suggest that 
viruses and bacteria do not fight; on the contrary they may 
even  cooperate  to  spread  the  infection. Therefore, 
suppressing  the  initial  viral  infection  is  key  to  preventing 
serious throat illness. If the infection is already established, 
associating  a  topical  antiviral  agent  to  a  topical  antiseptic 
becomes necessary to stop further infection and rid the throat 
of contaminants.  Many  antivirals,  antibacterials, antiseptics 
and common cold treatments are available, but none of these 
has the combined antiviral and antiseptic properties essential 
to  treat  throat  infection,  whereas  current  antiviral  drug 
development  is  still  limited  to  intracellular  virus  growth 
inhibitors. 
[5] The complexity of throat infection, necessity of 
a multi-target approach, impossibility of associating different 
molecules within a single drug and patenting a combination 
product,  have totally  hampered  pharmaceutical  R&D  for  a 
curative  pharyngitis  drug. 
[6]  This  review  focuses  on  the 
recent development of topical  virus glycoprotein inhibitors 
incorporated in glycerol as a topical antiviral and antiseptic 
throat  treatment  free  of  side  effect,  a  concept  which  may 
radically change the usage of existing antiviral drugs as well 
as  future  antiviral  research.  We  shall  briefly  examine  the 
events  inherent  to  viral  throat  infection,  the  symbiotic 
mechanisms of virus – bacteria interactions which cause and 
maintain  throat  infection,  the  available  antiviral  and 
antibacterial  drugs,  and  the  recently  launched  antiseptic-
antiviral  treatments  destined  to  revolutionize  the  future  of 
antiviral research targeting throat infections.
Main causes of throat infection
The  predominant  pathogens  in  upper  respiratory  tract 
infections  (URT)  are  viruses  of  the  Orthomyxoviridae
(influenza)  and  Paramyxoviridae (including  the 
parainfluenza  viruses  (PIVs),  human  respiratory  syncytial 
virus (RSV), and human metapneumovirus (hMPV) families, 
whose members are enveloped viruses. Nasopharyngitis may 
also  involve  other  viruses,  with  milder  frequency  and 
pathogenicity.  These  viruses  include:  the  omnipresent 
common  cough  rhinoviruses  (single-stranded,  non-
enveloped)  whose  multiplicity  of  serotypes  (over  100) 
seriously  handicaps  vaccine  development;  enteroviruses 
(coxsackieviruses  and numbered  enteroviruses);  and 
enveloped  viruses  (Coronaviridae family), containing 
positive-sense single-stranded RNA (ssRNA), among which 
the  human  coronavirus  (HCoV)  229E,  HCoV  OC43,  the 
severe  acute  respiratory  syndrome-associated  CoV  (SARS-
CoV), and the HCoV NL63 and HCoV HKU1 viruses, are 
known human pathogens. 
[7] Other DNA viruses involved in 
human upper or lower respiratory tract infections comprise 
non-enveloped  double-stranded  DNA  (dsDNA)  viruses 
(Adenoviridae), and  the  ssDNA  human  bocavirus  (HBoV) 
(Parvoviridae).  This  review  concentrates  particularly  on 
viruses  from  the  Orthomyxoviridae family  (containing 
influenza A, B, and C groups) since they are the prevalent 
infective agent of pharyngitis,  type A and B viruses causing 
epidemic flu illness, while the less common type C causes 
isolated mild disease, mostly in children. 
[8] The genome of 
Orthomyxoviruses  is  composed  of  minus-strand  RNA, 
containing  6  to  8  segments.  Influenza  A  and  B  species 
comprise  three  transcriptases  (PB1,  PB2,  and  PA);  two 
surface  glycoproteins,  hemagglutunin  (H  or  HA)  and 
neuramidase (N and NA); two matrix proteins (M1 and M2); 
and one nucleocapsid protein (NP). Sequence and antigenic 
analysis  allowed  differentiating  eighteen  H  (H1-H18)  and 
eleven  N  (N1-N11)  subtypes  in  animal  and  avian  strains, 
among which only H1, H2 and H3 and N1 and N2 are known 
to  engender  widespread  human  epidemics. 
[9-10] However, 
mutations  in progeny  genetic  structures  often  occur during 
influenza  virus  replication  and  the  minor  genetic  changes 
(known as antigenic drift) demand yearly influenza vaccines 
reformulation. 
[11-12]
Initial virus attack
In human beings, influenza typically causes sore throat, and 
sometimes pneumonia. Virus transmission is either airborne, 
as cough and sneezes produce aerosols which carry the virus, 
or  through  nasal  secretions or  contact  with  contaminated 
surfaces.  Viral  infections’  mode  of  progression  differs 
completely  between  topical  and  systemic  infections.  In  an 
external  topical  infection  such  as  influenza,  a  few  virus 
particles initially come into contact with throat mucosal cells, 
with practically no clinical signs at this stage. After initial 
contamination,  the  virus  multiplies  inside  the  cells  and 
millions of virions are then liberated topically, and in turn 
infect new cells and eventually create visible lesions. 
[13]
Role of proteases
Proteases, also known as proteinases or proteolytic enzymes, 
are  a  large  group  of  enzymes found  inside  or  outside  the 
cells,  particularly  in  the  vicinity  of  damaged  tissues  and 
chronic  wounds.    Involved  in  the  splitting  of  protein 
molecules  (catabolism),  they  have  an  essential  role  in 
creating  an  environment  conducive  to  tissue repair,  by 
facilitating  removal  of  proteinous  debris  generated  during 
tissue  breakdown  and interfering with the  healing  process. 
Proteases  are  divided  into  four  major  groups  according  to 
their mode of action: metalloproteinases or Matrix-Metallo-
Proteins  (MMPs),  serine  proteinases,  cysteine  (thiol) 
proteinases, and aspartic proteinases. Their exact number is 
not  yet  known,  however,  as  new  proteases  are  being 
discovered regularly. 
[14] 
They  are  also  implicated  in  virus-related  processes.  Virus 
entry  is  intimately  dependent  on  membrane  fusion,  whose 
activating factor  is the  host  cell’s  HA (0)  protease. 
[15] At 
least  seven  different  trypsin-type  processing  proteases, 
including  tryptase  Clara  and  tryptase  TL2,  have  been 
identified for HA (0) processing but there are probably many 
others not  yet identified. 
[16-18] In addition to the  proteases 
present  on  the  infected  throat surface,  intracellular  virus 
multiplication also encodes up to 11 proteins and this coding 
capacity  demands  that  the  virus  use  the  host  cellular 
machinery for many aspects of its life cycle, 
[19] including the 
help of different intracellular proteases. Thus, the influenza 
virus uses some specific proteases or enzymes present on the 
surface of the respiratory tract to penetrate and infect throat 
cells.  To  restrict  viral  infection,  our  body  defense 
mechanisms  liberate  anti-proteases,  called  secretory 
leukoproteases in the URT and pulmonary surfactants in the 
lower  respiratory  tract,  to  reduce  the  amount  of  proteases 
available  to  assist  viral  entry.  But  when  protease  activity Rousse et al. / Innovative Scientific Concept of Topical Virus Glycoprotein Inhibitors Incorporated…..……
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predominates  over  the  activities  of  inhibitory  compounds, 
viral  infection  cannot  be  stopped. 
[20] Body  defense 
mechanisms are activated to produce antibodies and to stop 
virus replication but this normally takes 5-10 days. This is 
the reason  why protease inhibitors may be pivotal and are 
being considered as potential future therapeutic agents for the 
treatment of influenza. 
[17, 21]
Virus surface glycoproteins
All  enveloped  viruses  possess  specific  proteins,  called 
glycoproteins  (Gps),  on  their  surface.  These  Gps  code  for 
virus antigenicity. As throat infection is caused chiefly by the 
influenza  virus,  we  will restrict our  Gp  description  to  this 
virus. A and B influenza species are difficult to differentiate 
even by microscopic examination, both appearing spherical 
or filamentous in shape, their size ranging from 100 nm in 
diameter for spherical forms to frequently over 300 nm in 
length for filamentous forms. Virions of the A species have 
Gp spikes, roughly 4 HA for 1 NA, jutting out from a host 
cell–derived  lipid  membrane,
[22] traversed  by matrix (M2) 
ion channels, with approximately one M2 channel per 10
1-
10
2 HA  molecules.  The  envelope  and  its  three  integral 
membrane proteins HA, NA, and M2 enclose the matrix of 
M1  protein  wrapping  the  central  virion  core.  The  nuclear 
export protein (NEP, aka nonstructural protein 2, NS2) and 
the ribonucleoprotein (RNP) complex, which consists of the 
viral RNA segments coated with nucleoprotein (NP) and the 
heterotrimeric RNA-dependent RNA polymerase, composed 
of  two  “polymerase  basic”  and  one  “polymerase  acidic” 
subunits (PB1, PB2, and PA) are inner  components  of the 
matrix. The influenza B virion structure is comparable (its 
envelope possessing four proteins, though: HA, NA, plus NB 
and BM2), whereas that of influenza C virions is different: 
on infected cells, they can  organize in long strings  on the 
order  of  500μm.  However,  influenza  C  virions  are 
compositionally similar: the matrix protein M1, enclosing the 
RNP  and  polymerase  complex  core,  is  covered  by  a  lipid 
envelope with a sole major surface Gp, the hemagglutinin-
esterase-fusion (HEF) protein, whose function is equivalent 
to  that  of  HA  and  NA in  A  and  B  types,  and  one minor 
envelope  protein,  CM2. 
[23-24] The  HA projecting from the 
influenza virus identify and bind the N-acetylneuraminic or 
sialic acid moiety on the host cell surface, favoring α-2, 3- or 
α-2, 6-linkages. The NA not only assists virus attachment to 
cells but could also enhance virus infectivity by facilitating 
access  into  the  respiratory  epithelium  and  epithelial  cells 
through mucin disintegration 
[25] and cleaving of sialic acid, 
which  may  regulate  HA  binding  to  the  host  cell  surface. 
Deleting NA from the influenza A virus’ genetic sequence 
dramatically curbs initiation of infection as nascent virions 
then  aggregate,  incapable  of  dispersing  through  a  cell 
monolayer.
[26-27] Since full infection is obtained through HA 
and  NA cooperation, a  topical  antiviral  drug should  target 
both surface Gps for efficient virus inhibition. 
[28] The virus 
penetrates the cell by endocytosis mediated by HA (or HEF 
in  influenza  C  virus)  – sialic  acid  binding.  The  acidic 
environment inside the endosomal compartment is necessary 
to virus uncoating, causing the HA to change shape and bare 
a  fusion  peptide  to  mediate  the  fusion  between  virus 
envelope  and  endosomal  membrane:  through  this  minute 
aperture,  the  virus’  genome  penetrates  into  the  host  cell 
cytoplasm
[29] and the released RNPs are then imported into 
the  host  cell  nucleus  through  viral  proteins’  nuclear 
localization signals (NLSs). 
[30] The nucleus is the synthesis 
site  of  all  influenza  RNA (messenger-RNA  (mRNA)  as 
template  for  host-cell  translation  of  viral  proteins,  and 
negative  strand  viral  RNA  segments  as  components  of 
progeny genomes). Membrane-bound ribosomes decode viral 
mRNA  to  synthesize  HA,  NA,  and  M2  proteins  into  the 
endoplasmic reticulum, to be conveyed to the Golgi body for 
post-translational modification. Apical sorting motifs on HA, 
NA,  and  M2  transmembrane  envelope  proteins  are 
recognized by the trans-Golgi network and determine their 
route  towards  the  site  of  virion  assembly  (including  the 
vRNP core) and morphogenesis, budding and release (likely 
initiated by M1 matrix protein): the plasma membrane. After 
budding is complete, HA-mediated binding of virions to host 
cell surface sialic acid continues until NA’s sialidase activity 
releases the virion progeny. 
[25, 30] Host antibodies to the NA, 
or  antiviral  neuraminidase-inhibiting  drugs,  stop  infected 
cells from expulsing the  virus and inhibit  viral replication. 
Shedding  of  fresh  virus  particles  onto  the  infected  surface 
after  initial  contamination  perpetuates  new  host  cell 
infection,  and  when  sufficient  cellular  damage  is  done, 
microscopical lesions appear on the surface of the pharynx 
where opportunistic bacteria, normally harbored there, start 
proliferating and cause secondary bacterial infection, much 
more  detrimental  to  the  throat  surface  than  the  damage 
caused through virus replication. 
Secondary bacterial infection
A  complex  ecosystem  of  commensals  and  opportunistic 
pathogens  (pathobionts),  including  Streptococcus 
pneumoniae (pneumococcus),  Haemophilus  influenzae, 
Moraxella catarrhalis and Staphylococcus aureus, populates 
the human URT. 
[31] Most of these bacterial species inhabit 
the nasopharyngeal mucosa in healthy individuals but their 
infectivity is neutralized by the body’s defenses and a healthy 
mucosal  barrier.  For  throat  infection  to  begin,  bacterial 
proliferation  and  colonization  of  URT  mucosa  must  take 
place,  which  occurs  much  more  easily  in  children. 
[32] In 
some  cases,  different  bacterial  species  strive  against  each 
other  while  in  other cases  they  collaborate  for  mutual 
benefits. 
[33-34]
Colonizing  tactics  include  production  of noxious  hydrogen 
peroxidase  (H2O2)  by  certain  bacteria  that  are  virtually 
immune  to  it (such  as  the  highly  H2O2-tolerant  S. 
pneumonia), in concentrations lethal even for bacteria able to 
produce  the  H2O2-neutralizing  enzyme  catalase,  such  as S. 
aureus
[35] and H. influenzae.
[36] Another strategy consists in 
preventing a competing microorganism from adhering to the 
host  epithelial  surface.  For  example,  pneumococcus-
expressed NA clips sialic acid from the lipooligosaccharides 
of some H. influenzae strains’ outer membranes, preventing 
virus  adhesion  to  nasopharyngeal  cells  and  subsequent 
colonization.
[37] Bacterial  adherence  to  host  cell  receptors 
may also be mediated by phosphorylcholine, a cell-surface 
molecule  expressed  by  both S.  pneumoniae
[38] and H. 
influenzae,
[39] but  essential  only  for  the  survival  of 
pneumococci.  H.  influenza can  therefore  produce 
phosphorylcholine,  trigger  host  immunological  reaction  to 
produce antibiodies, and neutralize S. pneumoniae.
[39-40] The 
host  immune  system  is  also  involved  in  interspecies 
competition,  by  eliminating  one  species  through 
complement- and  neutrophil-mediated  killing 
[41-42] or  by 
helping  the  survival  of  other  species through  immune 
evasion. 
[43] Microbial  interactions  appear  to  involve  a 
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characteristics, with a significant impact on both the severity 
of microbial infection and the strategy to develop an effective 
antibacterial drug. 
[44] Therefore, depending upon the state of 
immunity  of  the  host  and  the  predominance  of  bacterial 
species on the throat surface, the type of bacteria colonizing 
the  nasopharynx  may  vary,  requiring  a  broad  spectrum 
antimicrobial approach for throat infection relief.
Viral-Bacterial symbiosis
While throat infection is usually of viral origin, the clinical 
symptoms  are  predominantly  imputable  to  secondary 
bacterial infection. Although mortality from influenza alone 
is  possible,  clinical  severity  of  the  condition  increases 
dramatically  when  aggravated  by  bacterial  surinfection. 
Strong interactions exist between respiratory tract pathogenic 
viruses  and  native  bacteria,  particularly  between  influenza 
virus  and S.  pneumonia.
[45] Recent  findings  indicate  that 
these two pathogens act symbiotically.
The key mechanisms by which viruses cooperate to enhance 
bacterial infection may include:
Bacterial adhesion to throat mucosa
Viruses  sap  the  host  epithelium  defenses  and  render  URT 
mucosal  surfaces  even  more  vulnerable  to  pathogen 
attachment  and  subsequent  colonization.
[46] Virus-aided 
bacterial  attachment  occurs  not  only  in  presence  of 
simultaneous  infection,  but  also  up  to  a  week  after  initial 
viral  infection
[47-48] or  even  after  full  recovery  from  the 
flu.
[49]
Throat mucosa cell lyses
After initial attachment of a few virus particles, viruses grow 
inside  a  few  throat  mucosal  cells,  induce  cell  lysis,  and 
eventually  damage  the  epithelial  layer,
[50-51] exposing  the 
basement  membrane  matrix. It  was  observed  that  S. 
pneumonia,
[52] S. aureus and M. catarrhalis
[53] bind to ECM 
proteins, suggesting that these species could take advantage 
of  this  denudation.  Cellular  damage  also  triggers  the 
production  of  fibronectin  which  further  heightens  bacterial 
binding to the throat mucosa.
[48] Mucosal damage results in 
loss  of  epithelial  integrity  and  decreased  inhibition  of 
bacterial  translocation,  as  illustrated  by  rhinovirus-induced 
paracellular  migration  of H.  influenza.
[54] Ciliated  cells’ 
mucociliary  velocity  and  barrier  functions  may  also  be 
deteriorated by viruses. 
[51, 55]
Expression of defensin proteins
Inside  host  cells,  the  virus  may  cause  changes  in  the 
expression  of  antimicrobial  peptides,  or  defensins,
[56]
secreted  in  airway  mucosa,  and  whose  essential  innate 
immunity role is to eradicate harmful bacteria.
[56-57]
Topical inflammation
In epithelial cells, the  inflammatory response  prompted  by 
viral  infection  induces  the  upregulation  of  adhesion 
molecules which act as receptors mediating the attachment of 
immune  cells  to  virus-infected  cells  to  fight  and  clear  the 
infection, as illustrated by the intracellular adhesion molecule 
1  (ICAM-1),  outer  membrane  protein  P5-homologous 
fimbriae  (P5  fimbriae),  carcinoembryonic  adhesion 
molecule-1  (CEACAM-1),  and  platelet-activating  factor 
receptor (PAFr) in different cell types upon infection with a 
virus such as RSV or PIV. 
[48,  58] However, some bacterial 
species also bind to some of these adhesion proteins on the 
surface of host cells. 
[48,  59-61] For example, upregulation of 
ICAM-1 instigated by rhinovirus for its own invasion  will 
also  be  used  by H.  influenza.
[48,  62] Viral  infection  also 
increases  expression  of  natural  PAFr-ligand 
phosphorylcholine by certain strains of S. pneumoniae and H. 
influenza,  which  further  facilitates  their  adhesion  and 
invasion.
[48, 60-61]
Neuraminidase production by influenza virus
Influenza  viruses  produce  NA  whose  essential  function  of 
cleaving  terminal  sialic  acid  residues  clears  the  path  for 
bacteria  to  reach  their  receptors  on  the  surface  of  the 
URT.
[63-64]
Cellular mechanisms
Virus infection increases adhesion of neutrophils, monocytes, 
and other immune cells to virus-infected cells, resulting in 
pro-inflammatory  immune  response.  It  also  increases 
susceptibility  to  bacterial  superinfection  by  inducing 
impairment  of  neutrophil function, diminution  of oxidative 
burst,
[65-66] and intensified neutrophil apoptosis. 
[66-67] Some 
influenza virus strains may predispose to superinfection by S. 
aureus due  to  poor  recruitment  and  activation  of  natural 
killer  (NK)  cells.
[68] Viral  infection  may  also  modify 
biological  functions  of  monocytes,  resulting  in  lower  CD 
receptors surface expression,
[69] as well as of cytokines.
[70]
Thus,  virus-induced  interferon  (IFN)-α and  IFN-β  prompt 
ineffective  neutrophil  responses  due  to  a  diminished 
production  of  neutrophil  chemoattractants.
[71] Moreover, 
IFN-γ  decreases  the  activity  of  macrophages,
[72]
undermining  the  first  line  of  bacteria  removal.  Tumor 
necrosis  factor  (TNF)-α  production  is  also  downregulated 
during  viral  infection,  resulting  in  higher  vulnerability  to 
secondary bacterial infections.
[68] This proves that secondary 
bacterial infection is a very common phenomenon underlying 
complex  interactions  between  bacteria  and  viruses  during 
viral throat infection. Therefore, to be effective, a treatment 
should not only possess antiviral but also strong antibacterial 
properties.
An ideal treatment approach
An effective treatment should be capable of neutralizing the 
free virus particles present on the surface of the throat, so as 
to  stop  the  primary  cause  of  infection.  But  taking  into 
account the  amount  of virions on the  infected surface,  the 
role of virus entry-enhancing proteases and the extracellular 
location  of  the  virus  in  conjunction  with  the  microbial 
infection,  a  multi-level  approach  of  inhibiting  the  virus 
infection,  neutralizing  virus  entry-enhancing  proteases  as 
well  as  detaching  and  eliminating  microbial  contaminants 
from  the  throat  surface  is  essential  to  stop  and  cure  the 
infection. The treatment must be as rapid as possible, without 
side  effects  and  without  altering  the  normal  functions  of 
healthy cells.
Currently available antivirals
Antiviral drugs constitute one of the biggest research areas of 
the pharmaceutical industry. An ideal antiviral drug should 
inhibit  virus  replication  when  used  at  concentrations  not 
detrimental to the host, should be non-toxic and non-irritant 
if applied topically. Viruses infecting the pharynx are mostly 
present on the epithelial surface of the throat although a small 
number  of  virus  particles  continue  multiplying  inside  the 
cells.  Infected cells are bound to die and their lyses keep on 
liberating  new  virions  onto  the  throat’s  surface.  Stopping 
new infection is therefore the 1
st fundamental step for treating 
a viral throat infection. 
Current  treatment  strategies  include  the  use  of  vaccines, 
intracellular  virus  growth  inhibitors  such  as    amantadine, 
rimantadine,  ribavirin,  idoxuridine,  trifluridine,  vidarabine, 
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zalcitabine,  stavudine,  famciclovir  and  valaciclovir,  and 
throat gargarisms, but their modes of action are not adapted 
for the treatment of throat infections. These drugs are mostly 
used orally to treat herpes virus, enterovirus, and, to a lesser 
extent, rhinovirus and severe influenza infections, mainly by 
inhibiting viral development at various stages of the virus’ 
replication cycle.
Roughly, the virus replicative cycle can be divided into 10 
stages:  (1)  adsorption,  (2)  penetration,  (3)  uncoating,  (4) 
early transcription, (5) early translation, (6) replication of the 
viral genome, (7) late transcription, (8) late translation, (9) 
assembly, and (10) release of new virus particles. The first 
three replicative stages are specific to virus infection and do 
not occur in uninfected cells. Examples of virus replication 
steps  controlled  by  virus-specified  enzymes  include 
transcription of positive-sense RNA to DNA (catalyzed  by 
the  reverse  transcriptase  associated  with  retroviruses), 
replication  of  DNA  to  DNA  (catalyzed  by  the  DNA 
polymerases of herpes viruses), and proteolytic cleavage of 
viral precursor proteins (catalyzed by the protease of human 
immunodeficiency virus), but these events occur inside the 
cells and require the drug to be present inside the body. For 
the  treatment  of  throat  infection,  an  antiviral  drug  present 
systemically and acting on the viral replication may not have 
any  effect  on  the  free  virions  attacking  the  throat  surface 
from the outside. The mode of action of the commonly used 
antiviral drugs is as follows:
Amantadine and rimantadine
These two  antiviral agents are  administered  orally  and  are 
suggested  in  severe  cases  of  influenza  A.  They  block  the 
H
+ ion  channel  of  the  M2  protein  membrane  found  on 
influenza  A  viruses.  This  inhibits  the  acidification  of  the 
interior  of the  virus and  ultimately prevents  the release  of 
viral RNA. 
[73] When administered orally within 48 hours of 
the onset of symptoms, these drugs can reduce the severity of 
symptoms and lessen the duration of influenza A illness by 
approximately  24  hours.  Despite  their  efficacy,  these 
antivirals are not widely used because they have no effect on 
virions  present  on  the  throat  surface,  lack  activity  against 
influenza B viruses, carry significant risk of side effects for 
the central nervous system (especially amantadine), and can 
rapidly select for drug resistance mutations during treatment. 
Acyclovirs
Related  to  cytarabine,  idoxuridine,  trifluridine  and 
vidarabine,  acyclovirs  are  nucleoside  analogue  antiviral 
drugs.  Like  the  earlier  antivirals, acyclovir only  shows 
activity against some members of the herpes group among 
the  DNA  viruses.  Despite  evidence  of  efficacy  in ocular 
herpetic keratitis, as well as initial and primary genital herpes 
infection,  acyclovir  offers  virtually  no  clinical  benefit  in 
throat infection. Topical ointment proved moderately helpful 
in treating recurrent genital herpes by shortening its course 
by  a  couple  of  days.  Oral  and  intravenous  acyclovir was 
beneficial in initial genital herpes infections as it abbreviated 
recurrent outbreaks by 1 to 2 days, but had no effect on pain 
and  other  symptoms.  In  non-immunocompromised  patients 
with  recurrent  herpes  simplex  labialis,  little  clinical 
amelioration  was  derived  from  topical acyclovir ointment, 
even  with  therapy  initiation  in  prodromal  phase,  while 
topical acyclovir cream  produced  modest  yet  significant 
improvements  in  the  clinical  but  not  the  symptomological 
course of the disease. 
[74] Despite some aspects of the drug's 
use  in  severe  herpes  infection, acyclovir-containing  drugs 
have no topical effect on virus growth and have multiple side 
effects when given orally. 
Neuraminidase inhibitors
NA is a surface Gp common to both types of influenza. Its 
enzymatic  activities are  essential for the release  of  virions 
from infected cells and prevention of virus aggregation at the 
host cell surface. 
[75] NA inhibitors, such as oseltamivir and 
zanamivir,  have  no  effect  on  virus  present  on  the  throat 
surface but can used orally or by inhalation for the treatment 
of  uncomplicated  acute  influenza  A  and  B  infections  if 
administered within 48h of onset of symptoms as otherwise 
these drugs have no beneficial effects, 
[76-77] and may cause 
adverse effects (such as transitory nausea with oseltamivir). 
[78] Because early administration of these drugs is essential, 
yet they have no efficacy on free virus particles present on 
the throat surface, have minor but multiple side effects 
[79]
and are known to develop virus resistance to neuraminidase 
inhibitors, 
[80] they are limited to severe cases.
New intracellular antivirals
Many  new  antiviral  drugs  are  under  development  but  are 
almost  all  directed  to  stop  intracellular  virus  growth  and 
require oral administration. Because of the close interaction 
between virus replication and normal cellular metabolism, it 
is  very  difficult  to  interrupt  the  virus  replicative  cycle 
without adversely affecting host cell metabolism. However, 
some of the events in the virus replicative cycle either do not 
occur in normal uninfected cells or are controlled by virus-
specific  enzymes  that  differ  structurally  and  functionally 
from the corresponding host cell enzymes.  Future antiviral 
drug research is directed to act on these events to avoid side 
effects. 
[5-6]
As indicated before, during respiratory infection, most of the 
virus is present on the infected surface, and only a topical 
antiviral drug may have the therapeutic potential to reduce 
the  continuously  perpetuated  virus  attack.  However,  such 
treatments may not be able to cure the infection if they do not 
neutralize virus entry-enhancing proteases and get rid of the 
microbial contaminants.
Vaccines 
Vaccination  is  the  most  effective  strategy  to  prevent, or 
lessen  the  severity  of, influenza  and  subsequent  throat 
infection. But, despite the influenza-associated morbidity and 
mortality, vaccines are used in barely 30% of the population. 
[81] Vaccine  efficacy  is  contingent  on  the  antigenic  match 
between the strains in the epidemic and those contained in 
the vaccine, as well as on the recipient’s age and immune 
status. Yearly vaccine reformulation comprises the two type 
A  and  one  type  B  strains  with  the  highest  probability  of 
circulating that  season.  Adequate antigenic  correspondence 
allows curbing influenza infection or severity in roughly two 
thirds of the vaccinated population, helping protect them, if 
not from pharyngitis,  from the more  serious  complications 
leading  to hospitalization or  even  death. 
[82] New  vaccines 
able to completely block the infection are needed to convince 
“at risk” populations to accept vaccination. Vaccination also 
presents  the  disadvantages  of  a  lag  period  between 
inoculation  and  its  effectiveness  (approximate  3  weeks), 
absence  of efficacy to neutralize free  virions  on the throat 
surface,  necessity  of  medical  personnel  for  injection, 
relatively  high  cost,  and  poor  antigenicity  profile  in  many 
cases. The use of trivalent, live, attenuated intranasal vaccine 
in the future is under assessment as such vaccines may offer 
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responses resulting in significantly higher protection against 
influenza  than  inactivated  vaccines.  However,  initial  tests 
show  that  although  incidence  of  severe  febrile  illness  and 
febrile  URT  infection  was  lessened  by  trivalent  live 
attenuated vaccination compared to placebo groups, infection 
and fever still persisted. 
[83]
Antibiotics and anti-inflammatory drugs
Antiobiotics have  no effect on viral growth but the use of 
antibiotics to avoid secondary bacterial complications is very 
prevalent, particularly in developed countries. Streptococcus
and mainly group A β-hemolytic streptococcus (GABHS) are 
commonly  found  in  throat  infections.  GABHS  are  very 
sensitive  to  penicillin  V  because  the  bacterium  cannot 
manufacture  β-lactamase.  First-line  drugs  for  bacterial 
pharyngitis  therefore  include  penicillin,  ampicillin  or 
amoxicillin. 
[84] Erythromycin  and  first-generation 
cephalosporins  (CG)  represent  reasonable  alternative 
treatments,  particularly  in  cases  of  non-life-threatening 
allergy  to  penicillin,  failed  response  to  penicillin  or  re-
infection following penicillin therapy. 
[84-85] Since GABHS is 
a  prevalent  infective  agent,  fluoroquinolones,  and 
sulfamethoxazole/trimethoprim showing poor activity against 
Gram-positive  pathogens  are  not  the  best  choice  of 
antibiotics,  whereas  the  more  efficient  amoxicillin-
clavulanate,  clarithromycin,  azithromycin  and  second-
generation cephalosporins are only third-line options as their 
broader spectrum heightens bacterial resistance potential. A 
5-7  day  course  has  proved  clinically  effective  in  reducing 
bacterial load, but mean duration of illness is shortened by 
less than 1 day, with no difference in time off from work, and 
antibiotics  have  generally  limited  effect  on  sore  throat 
symptoms  while  presenting  the  risk  of  causing  resistant 
bacteria strains to emerge. 
[86-87] Headache, pain, and fever 
are usually slightly less severe when patients having positive 
GABHS cultures are treated with antibiotics. Antibiotherapy 
would  also  help  reduce  the  risk  of  pharyngitis  being 
compounded  by  other  local  infections  (e.g.  otitis and 
sinusitis).  However, these  minor benefits  must be  weighed 
against  antibiotics-induced  side  effects  such  as  vomiting, 
diarrhea,  abdominal  pain,  and  rashes,  as  well  as  allergic 
reactions to penicillin. 
[88]  
In  addition  to  antibiotherapy,  corticosteroids,  including 
cortisone,  hydrocortisone and  prednisone,  also  constitute  a 
common  symptomatic  relief  treatment,  chiefly  to  alleviate 
throat  pain  in  participants  with  severe  URT  infection. 
[89]
Corticosteroids mimic the effects of adrenal hormones that 
can  reduce  the  signs  and  symptoms  of  inflammatory 
conditions but can also suppress the immune system, which 
can  help  control  autoimmune  conditions.  They  are 
administered orally, intravenously, by inhalation, or topically 
for a period of maximum 3-4 days due to high risk of side 
effects. Fluid retention and lower extremity oedema, raised 
intraocular  pressure  and  blood  pressure,  mood  swings, 
weight gain with fat deposits in the abdomen, easy bruising 
and  slower  wound  healing  are  the  main  side  effects  of 
systemic  administration. 
[90] Topical  corticosteroids 
application  on the  throat  surface may  cause  coughing,  dry 
throat  and  red  sores  in  that  area. 
[91] Despite  numerous 
scientific studies gathering evidence that systemic or topical 
antibiotic  or anti-inflammatory  treatments offer little  or no 
benefit to most patients with throat infection, antibiotics are 
globally  overprescribed  for  URT  conditions  with  an 
increasing risk of bacterial resistance. 
[92-93]
Alternative treatments
Despite  limited  and  conflicting  evidence available  in  the 
literature, the use of alternative or natural remedies is on the 
rise, reflecting the poor efficacy of currently available drugs 
to treat nasopharyngeal infection. Some of the most popular 
yet controversial remedies are zinc lozenges and echinacea.
Zinc
Several mechanisms by which zinc may be effective against 
throat infection have been considered. At a concentration of 
about 0.1mmol/L, zinc blocks in vitro rhinovirus replication 
by preventing viral capsid protein formation. 
[94] It may also 
have immunomodulating properties, inducing production of 
interferon 
[95] to halt bacterial and viral growth.  Zinc’s cost 
and  potential  for  side  effects  (unpleasant  taste,  mouth 
irritation, and gastrointestinal disturbances) are minor, but, as 
some clinical studies showed only a very slight reduction in 
duration of cold  symptoms, zinc lozenges should rather be 
used as a complementary remedy, safe for short-term use in 
adults. 
Echinacea
Echinacea  is  acquiring  some  reputation  as  remedy  for 
common  cold  and throat  infection  in  the  US.  This  herb 
supposedly  exerts  its  action  through  nonspecific 
immunomodulatory  properties.    Data  from  well-designed 
clinical trials supporting its efficacy are scarce, yet echinacea 
is used extensively. Early treatment initiation may decrease 
the  severity  and  duration  of  acute  respiratory  infections 
[96] but data with standardized dosages and formulations are 
needed  to  conclusively  recommend  it  as  common  cold 
treatment.  Echinacea  appears  to  be  generally  free  of  toxic 
side  effects 
[97] but  a  theoretical  risk  of  nonspecific 
stimulation of the immune system excludes its use by people 
with autoimmune disorders or receiving immunosuppressant 
drugs,  as  well  as  in  HIV  positive  patients,  patients  with 
progressive  systemic  diseases,  such  as  tuberculosis  and 
multiple  sclerosis,  or  with  a  known  allergy  to  plants  of 
the Asteraceae family. 
[98-99]
Vitamin C
Large  doses  of  vitamin  C  are  widely  believed  to  prevent 
colds  or  relieve  symptoms.  However,  several  large-scale, 
controlled  studies  conducted  in  pediatric  and  adult 
populations to ascertain this popular theory failed to generate 
conclusive  evidence  that  the  vitamin  lessens  severity  or 
duration of symptoms. 
[100] It should actually be used with 
caution,  especially  in  the  eldest  and  the  youngest,  as 
prolonged use in large amounts may cause severe diarrhea.
Honey
Honey  has  been  traditionally  used  for  the  treatment  of 
wounds,  and  to  soothe  coughs  or  sore  throats. 
[101]
Application  of  honey  on  the  throat  may  help  reduce  local 
irritation  as  well  as  exert  some  osmotic  effect  to  detach 
microbial  contaminants.  Honey  has  also  been  shown  to 
possess  antioxidant  properties,  probably  owing  to  its  high 
vitamin  and  total  polyphenolic  content.  It  was  further 
observed to act as an antibacterial against S. aureus and E. 
coli, supposedly  thanks  to  generation  of  H2O2 or  to  its 
lysozyme content. 
[102]
Although  honey’s  antiviral  capacities  are  still  debated,  its 
antimicrobial  and  soothing  properties,  absence  of  bacterial 
resistance and easy availability, make it a product of choice 
for minor throat infections. 
[103]
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Sore or strep throat usually involves microbial colonization 
of the pharyngeal mucosal surface, causing inflammation and 
erythema.  Gargling  with  a  solution  that  is  saltier  than  the 
body  fluids  (i.e.  a  hypertonic  solution)  should  generate 
osmosis  and  help  clean  the  throat  surface.  The  underlying 
principle  is  that  if  a  semi-permeable  membrane  separates 
dilute  and  concentrated  solutions  then  the  dilute  solution 
permeates  through  the  membrane  into  the  concentrated 
solution,  the  process  going  on  until  the  concentrations  are 
equal on both sides. Salt water is more concentrated than the 
water  inside  bacteria  and  will  draw  out  water  from  the 
bacteria,  leading  to  their  dehydration  and  death  through 
plasmolysis. 
[104] Besides  osmotically  inducing  lysis  of 
bacteria,  the  outward  exudation  of  hypotonic  liquid  also 
helps  to  detach  bacteria  and  reduce  their  concentration. 
Additionally, salt water gargling helps to wash away excess
mucus  and  increase  blood  flow  to  the  throat.  Dilation  of 
capillaries  allows for faster circulation of infection-fighting 
cells. Another benefit of salt water is that it helps neutralize 
acids in the throat, restoring the natural pH balance that had 
been  disrupted  in  the  sore  throat.  As  a  consequence,  the 
burning  sensation  is  relieved  and  the  mucous  membranes 
become less irritated, which helps speed up the healing. 
Unfortunately, the hypertonic properties of water containing 
3-3.4%  salt  are  not  strong  enough  to  detach  all  the 
contaminants from the throat surface, whereas increasing that 
concentration  would  cause  strong  irritation.  Salt  water 
therefore  provides  temporary  relief  but  requires  frequent 
gargles (4-5 per day), which is not very practical. 
[105]
Future developments
Although  in-vitro some  substances  demonstrated  activity 
against viruses implicated in URT infections, when tested in 
live  patients  their  effectiveness  proved  unsatisfactory, 
probably  because  of  the  high  antigenicity  of  the  viruses 
involved. An emergent pharmacological target consists in a 
recently  isolated  cellular  receptor  responsible  for  cell 
attachment  common  to  most  rhinovirus  serovars:  the 
intercellular  adhesion  molecule  (ICAM-1).  Tremacamra,  a 
recombinant soluble form of ICAM-1, has been investigated 
for its capacities to inhibit URT viruses’ adhesion to mucosal 
cells but clinical results are inconclusive. 
[106]
Limitations of Antiviral Drugs
As  mentioned  above,  clinical  use  of  currently  available 
antiviral  drugs  is  limited  to  intracellular  virus  growth 
inhibitors  that  unfortunately  present  noxious  side  effects. 
There are no topical antivirals with the exception of a few 
topical  Gp inhibitors  recently  authorized for  topical use  in 
Europe.
[107-108] Besides, current antiviral drugs also present 
some  shortcomings:  high  selectivity  comes  with  the 
drawback  of  a  restricted  activity  spectrum,
[109] whereas 
viruses with the ability to lie dormant (such as Herpesviridae
or  Retroviridae viruses)  can,  in  their  latent  state,  evade 
antiviral therapy which targets active replication processes.
[110-111] Furthermore,  while  antiviral  treatment  should  be 
initiated as soon as possible to prevent tissue damage, correct 
early  diagnosis  or  viral  infections  is  often  elusive.
[76-77]
Finally, antivirals, as all antimicrobial agents, are susceptible 
to  drug  resistance,
[112-113] as  illustrated  by  highly  drug-
resistant mutant HIV strains in some AIDS patients, in whom 
acyclovir-resistant  HSV  or  VZV  strains  have  also  been 
detected. 
[114] This  points  out  the  dire  need  for  alternative 
approaches in antiviral drug design so as to circumvent such 
limitations. Scientific development of newer molecules with 
a greater efficacy, finer targeting of virus-specific functions, 
conceivably better safety profiles, may thwart resistance of 
mutants and allow greater virus inhibition, but the treatment 
of  viral  throat  infection,  involving  symbiotic  activity  of 
viruses  and  bacteria  on  the  throat  surface,  still  remains  a 
relatively uncharted scientific R&D field.
New virus glycoprotein inhibitors
Of  all  antimicrobial  treatments  available,  gargling  with 
hypertonic salt water or sea water (solutions containing 3 to 
3.4% salt) has been found to be the most effective and safe 
treatment  to  minimize  the  amount  of  free  virus  particles, 
bacteria  and  other  contaminants  on  the  throat  surface. 
However, despite their reasonable efficacy and good safety 
profile,  such  hypertonic  saline  solutions  aren’t  used  often 
because they prove too irritating, lack filmogen action, have 
a  short-lived  or  limited  efficacy,  and  cannot  be  patented. 
Increasing the salt concentration may have proved effective 
but  a  concentration  above  3.4%  salt  in  water  induces  the 
liberation of fucose, metacholine and histamins which are too 
highly irritant to be tolerated by the throat mucosa. 
[115]
Therefore,  a  French laboratory (Vitrobio) identified a  non-
irritant, cell-friendly, glycerol-type solution called VB-Gly, 7 
times  more  osmotically  active  than  sea  water. 
[116] An 
improved  version  of  this  solution,  with  enhanced  film 
retention  capabilities,  was  invented  and  patented  by  this 
laboratory  in  2013. 
[117] Through its  high  osmotic  activity, 
VB-Gly induces instant exudation of hypotonic fluids across 
the mucosal surface of the throat, thereby cleaning the entire 
surface  of  all  contaminants  present,  including  viruses  & 
bacteria,  and  acting  as  an  instant,  natural  antiseptic, 
antimicrobial, and hydrating solution. Vitrobio scientists also 
observed that plant tannins are very big, inert plant molecules 
which  have  a  strong  affinity  for proteins  and  other 
macromolecules 
[118] and can therefore bind to viral Gps such 
as  the  H1  and  N1  on  the  influenza  virus  capsid. 
[119-120]
Tannin–protein binding being specific, multiple experiments 
were conducted by incubating several plant tannins, or their 
specific fractions such as procyanidins (PCDs), with variable 
virus concentrations to evaluate tannin–virus Gp binding. 
[121]
Finally,  the  researchers  selected  specific  tannins  or  tannin 
fractions capable of binding with any one of the virus surface 
Gps as a new hypothesis to neutralize the influenza virus on 
the throat surface. Once a free virion binds with tannin, that 
virus particle cannot enter the cells anymore and, as a result, 
progression  of  the  viral  infection  is  stopped.  Similar 
experiments  were  conducted  to  find  tannins  capable  of 
binding  and  neutralizing  virus  entry-enhancing  proteases 
found on the infected throat surface. 
[14] Neutralizing viruses 
and  virus  entry-enhancing  proteases  constitutes  the  best 
solution  to  stop  virus  infection  without  any  cellular 
interaction  on the  pharyngeal  mucosa.  This  specific tannin 
combination was then incorporated in the hypertonic VB-Gly 
solution for topical application to treat multiple viral diseases 
such  as  labial  herpes, 
[122] genital  herpes, 
[108] and 
rhinosinusitis. 
[107] In  addition,  the  proteases  involved  in 
facilitating influenza virus entry into throat cells were also 
identified and similarly neutralized with specific plant tannin 
fractions. 
[14] The final selection of tannins incorporated in 
VB-Gly to treat throat infections was designed as a topical 
throat spray, totally safe and perfectly suited for application 
as a thin film on the throat surface. Owing to the filmogen 
properties of VB-Gly, the product film remains on the throat 
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for tannin-virus or tannin-protease binding, followed by their 
expulsion  through  hypotonic  liquid  exudation,  the  flow  of 
which also detaches and eliminates other contaminants from 
the  throat  surface  within  a  few  minutes.  Exerting  its 
antimicrobial effect mechanically, such a treatment does not 
pose any risk of bacterial or viral resistance, and the absence 
of  any  pharmacological,  biological,  metabolic,  or  cellular 
interactions with the underlying cellular layer, guarantees the 
absence of possible toxic side effects. The product film also 
protects  the  throat’s  surface  from  dryness,  irritation  and 
external aggressions, thus contributing to reducing pain. 
Clinical efficacy of new virus Gp and protease inhibitors 
Because  of  difficulties  in  quantifying  the exact  number  of 
virus-infected cells on the throat surface (due to swallowing 
and throat  mobility),  it  was  decided  that a  clinical trial  to 
evaluate the efficacy of topical antivirals should initially be 
conducted in adult  men and women (n=60) suffering from 
labial herpes, using herpes surface gB and gC Gp-inhibiting 
tannins. 
[122] A few drops of product (anti-herpes tannins in 
VB-Gly solution) were directly applied on the open herpes 
lesions (3-4 applications per day) for a maximum period of 
14 days. Virus-infected cells were collected from the lesion 
with a swab before treatment and then 2 hours, and 4, 7 and 
14  days  after  the  start  of  treatment.  Virus  amount  was 
quantified using Tzanck test. Results showed above 750 (± 
17.72)  virus-infected  cells  in  each  lesion  at  the  start  of 
treatment. Just 2h after first drug application, the quantity of 
free virions was diminished by 38% (465 ±10.82) indicating 
that the test product eliminates virus from the open lesions. 
Reduction  in  virus  concentration  inside  the  lesion  reached 
52% after 4 days of treatment, 70% after 7 days and 100% 
after 14 days of treatment. As increased liquid exudation was 
observed  during  the  first  5-10  minutes  following  each 
product application, it was postulated that while the tannins 
bind the free virus particles, the osmotic imbalance caused by 
the VB-Gly base resulting in an outward flow of hypotonic 
liquid from the lesion drains the conjugated virus particles 
from the lesion. This clinical outcome, added to previous in 
vitro results,  proves that  tannins  effectively  bind  the  virus 
surface Gps and stop new virus infection.
To analyze the clinical efficacy of topical virus Gp-inhibiting 
tannins  in  VB-Gly against  viral  throat  infection,  a clinical 
trial was then conducted with a product containing influenza 
virus-neutralizing  tannins  (VB-Th4)  in  patients  suffering 
from acute influenza-associated sore throat. 60 patients (adult 
men  and  women)  were treated  with  VB-Th4  spray  over  a 
period  of  14  consecutive  days  (3-4  applications  per  day) 
while  43  patients  in  the  control  group  received  other 
commonly used treatments. 
[123] Variations in total bacterial 
count on the throat surface was measured by collecting throat 
swabs  and  counting  the  number  of  colony-forming  units 
(cfu/cm
2),  before  1
st treatment,  2h  after  1
st treatment,  and 
then  on days 4, 7, 10 and 14 or up to complete  recovery. 
Throat  pain,  local  throat  irritation  and erythema  were  also 
measured,  on  a  0  to  10  scoring  scale,  to  evaluate  clinical 
signs caused by bacterial infection. Complete haematological 
analyses, blood biochemical parameters, renal function tests 
were also performed at the start and at the end of the study to 
exclude any eventual  possibilities  of  systemic  interference. 
Control  group  patients were  asked  to  take  any  treatment 
prescribed  by  their  clinical  ENT  specialist  and  were 
evaluated  similarly  to  patients  treated  with  VB-Th4. 
Participants in both groups were authorized to take systemic 
antibiotics  if  found  necessary  by  the  investigator.  Results 
indicate that on day 1, before treatment as well as 60 min 
after 1
st application of VB-Th4, all patients were positive for 
bacterial throat  infection.  However,  only 20/60 patients  on 
day 4 and 17/60 on day 7 showed presence of bacteria above 
the normal limits. All patients had a normal bacterial count 
from day 10 onwards. The number of bacteria measured in 
throat  swabs  before  VB-Th4  application  exceeded  the 
counting  limits  of 1950 (±179.43) cfu/cm
2.  As soon as  2h 
after  1
st product  application  the  mean  bacterial  count  was 
reduced to 1887.2 (±127.28) cfu/cm
2; then the values went 
down to 745.6 (± 39.84) cfu/cm
2 on day 4 and 374 (± 39.84 ) 
cfu/cm
2 on day 7, with normal values (50-100 cfu/cm
2) from 
day 10 onwards. Progressive and significant reduction was 
observed in throat pain, redness and irritation compared to 
the  patients  receiving  other  treatments.  The  number  of 
patients who stopped all treatments after 2 days because they 
felt they had completely recovered represented 31% in the 
VB-Th4 group (n=60) compared to only 11% in the control 
group  (n=43)  treated  with  antiseptic  sprays  (28/43),  salt 
water gargles (13/43) or expectorants (2/43). On the 7
th day 
of treatment, 61% participants in the VB-Th-4 group stopped 
treatment due to recovery, compared to 25% in the control 
group. On day 10 almost all the patients (95.0%) in the VB-
Th4 group had stopped treatment (57/60) compared to 28/43 
patients  (65.1%)  in  the  control  group.  These  results 
correspond to the absence of bacterial infection observed in 
most patients right after the 2
nd day of treatment. During the 
14-day study period, only 4/60 patients (6.66%) in the VB-
Th4 group required antibiotherapy for an average duration of 
7.1 day compared to 14/43 patients (32.56%) in the control 
group  for  an  average  period  of  9.8  days.  No  topical  or 
systemic  side  effects  or  any  undesirable  reaction  were 
observed in any of the patients. None of the haematological, 
blood biochemical,  or renal parameters was affected in the 
VB-Th4 group, indicating that the product’s mode of action 
remains totally topical and mechanical.
Viral  throat  infection,  accompanied  by  secondary  bacterial 
infection, remains one of the most prevalent health problems 
in the world. 
[124] Although this condition is rarely mortal for 
the patients, it has a considerable socio-economic impact. In 
spite of tremendous medical progress, there is, currently, no 
effective topical antiviral available in the world. Almost all 
antiviral  drugs  are  intended  to  stop  virus  growth  at  the 
intracellular level but have no effect on free virus particles 
present on the throat surface and are therefore of little or no 
use to treat topical viral infections where almost all the virus 
is active on the infected surface. As these antiviral drugs act 
intracellularly by modifying one of the mechanisms essential 
to cell survival, they stop viral growth but at the same time 
alter  normal  cellular  functions,  thus  inducing  various  side 
effects.  Viral  and  bacterial  resistance  to  all  currently 
available  treatments  is  the  second  biggest  concern for  all 
virus-induced  throat  infections. 
[125] Other,  less  harmful, 
treatments, such as salt water gargling, only help reduce the 
amount of contaminants on the throat surface but cannot stop 
the  infection  totally  and  therefore  may  only  be  used  to 
minimize clinical symptoms. 
Recently  developed  virus  glycoprotein  inhibitors 
incorporated into an  osmotically active  hypertonic solution 
for topical application, conceived only with natural and non-
toxic ingredients and capable of instantly eliminating viruses Rousse et al. / Innovative Scientific Concept of Topical Virus Glycoprotein Inhibitors Incorporated…..……
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and  other  microbial  contaminants  from  the  throat  surface
represent  the  safest  and  most  logical  scientific  approach. 
Hopefully,  those  newly  conceived  drugs,  based  on  this 
innovative concept, will contribute to offer a multifactorial 
topical treatment for virus-induced throat infections.
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